Bruker Launches iNTApharma for Native-State Nanoparticle Analysis in Biopharma
Event summary
- Bruker introduced iNTApharma, a label-free platform for nanoparticle characterization in mRNA drug and gene therapy development.
- The platform provides single-particle sensitivity for quantitative analysis of nanoscale bioparticles in native aqueous media.
- iNTApharma delivers size and concentration measurements within minutes, supporting research, therapy development, and quality control workflows.
- Initial systems will be placed with early-access partners in H1 2026, with broader commercial availability planned for H2 2026.
The big picture
Bruker's iNTApharma targets the growing need for high-precision, native-state characterization of viral vectors, lipid nanoparticles, and other nanoscale bioparticles in the rapidly expanding mRNA drug and gene therapy markets. The platform's ability to provide direct, unlabeled measurements aligns with industry trends toward more accurate and efficient quality control in biopharma research and development.
What we're watching
- Market Adoption
- The pace at which early-access partners integrate iNTApharma into their workflows will indicate its real-world utility.
- Competitive Positioning
- Whether Bruker can differentiate iNTApharma in a crowded field of nanoparticle characterization tools.
- Regulatory Impact
- How native-state analysis requirements evolve in biopharma quality control and their influence on iNTApharma's adoption.
Related topics